Journal article

Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis

Tomas Kalincik, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Jeannette Lechner-Scott, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Claudio Solaro, Francois Grand'Maison, Raymond Hupperts, Julie Prevost, Patrizia Sola, Diana Ferraro, Murat Terzi, Ernest Butler Show all

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2018

Abstract

OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. METHODS: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed. RESULTS: The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on ..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was financially supported by National Health and Medical Research Council of Australia (project grants 1129189 and 1083539 and practitioner fellowship 1080518). The MSBase Foundation is a not-for-profit organisation that receives support from Merck, Biogen, Novartis, Roche, Bayer Schering, Sanofi Genzyme and Teva.